Laboratorios Farmaceuticos Rovi, S.A. (VIE:ROVI)

Market Cap	4.23B +60.2%
Revenue (ttm)	743.48M -2.7%
Net Income	140.44M +2.6%
EPS	2.75 +2.7%
Shares Out	n/a
PE Ratio	30.10
Forward PE	26.94
Dividend	0.76 (0.95%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	n/a
Open	82.00
Previous Close	82.60
Day's Range	81.80 - 82.45
52-Week Range	45.82 - 84.80
Beta	n/a
RSI	58.76
Earnings Date	May 6, 2026

About VIE:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 1,998
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2025, VIE:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.